Taro Pharmaceutical Industries Ltd
F:TAL

Watchlist Manager
Taro Pharmaceutical Industries Ltd Logo
Taro Pharmaceutical Industries Ltd
F:TAL
Watchlist
Price: 40 EUR 1.01%
Market Cap: 1.5B EUR

Operating Margin
Taro Pharmaceutical Industries Ltd

3.4%
Current
13%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
3.4%
=
Operating Profit
21.5m
/
Revenue
629.2m

Operating Margin Across Competitors

No Stocks Found

Taro Pharmaceutical Industries Ltd
Glance View

Market Cap
1.5B EUR
Industry
Pharmaceuticals

In the often-underappreciated realm of generic pharmaceuticals, Taro Pharmaceutical Industries Ltd. has carved out a notable niche for itself. Founded in 1950 in Haifa, Israel, Taro's journey began with a focus on dermatological products, a specialism that continues to be at the heart of its operations. As generic drug prices have become increasingly competitive, Taro has distinguished itself through a robust portfolio that not only includes dermatology but also topical and oral medications across various therapeutic areas. The company's commitment to quality and cost-effective drug solutions stems from its strategic use of rigorous R&D efforts, channeling years of scientific expertise to bring affordable healthcare solutions to markets worldwide. In essence, Taro crafts a business model that balances operational efficiency with the nuanced complexities of pharmaceutical manufacturing and compliance. Underpinning Taro's business strategy is its prowess in generic drug manufacture, where it maximizes its revenue by capitalizing on patent expirations from mainstream pharmaceutical enterprises. With its deep understanding of regulatory frameworks and market dynamics, Taro adeptly navigates the intricate landscapes of the U.S. and international markets, leveraging its wide distribution network. The United States, being a major revenue driver, reflects Taro's prowess and its ability to quickly adapt to drug lifecycle shifts. Yet, Taro's success isn't solely attributed to scale but also to its meticulous cost management and operational synergies across its global facilities. This orchestration allows it to maintain competitive pricing while ensuring high-quality standards - a testament to its deep-rooted industry experience and strategic foresight.

TAL Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
3.4%
=
Operating Profit
21.5m
/
Revenue
629.2m
What is the Operating Margin of Taro Pharmaceutical Industries Ltd?

Based on Taro Pharmaceutical Industries Ltd's most recent financial statements, the company has Operating Margin of 3.4%.

Back to Top